Research at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. has led to the identification of sulfonylpiperazinyl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) inhibitors and reported to be useful for the treatment of gram-negative bacterial infections.
Researchers from Kanaph Therapeutics Inc. have reported the discovery and preclinical evaluation of a small-molecule EGFR inhibitor, KNP-501, being developed as an anticancer agent.
Amgen Inc. and Tscan Therapeutics Inc. have entered into a multi-year collaboration that will use Tscan’s proprietary target discovery platform, Targetscan, to identify the antigens recognized by T cells in patients with Crohn’s disease.
Cell cycle dysregulation in cancer cells represents a clinical option for treating cancer, by using cyclin-dependent kinase 4/6 (CDK4/6) inhibitory agents. Further evaluation on this approach was presented by TYK Medicines Inc., where they focused on the pharmacological action of a CDK7 inhibitor TY-2699a for the potential treatment of cancer.
Rocket Pharmaceuticals Inc. has received IND clearance from the FDA for RP-A601, an AAV.rh74-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy due to plakophilin 2 pathogenic variants (PKP2-ACM). RP-A601 offers the potential for a one-time, curative alternative to medical therapy, implantable cardioverter defibrillators and ablations.
RSS
